Combination therapy with the type II anti-CD20 antibody obinutuzumab
Author:
Affiliation:
1. Roche Pharmaceutical Research & Early Development, Roche Innovation Center Zurich, Zurich, Switzerland
2. Pharma Development Clinical Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland
Funder
F. Hoffmann-La Roche Ltd
Publisher
Informa UK Limited
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/13543784.2017.1373087
Reference162 articles.
1. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
4. Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study
5. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861;Toxins;2022-07-13
2. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology;Recent Patents on Anti-Cancer Drug Discovery;2020-12-29
3. Immunomodulatory Agents in Follicular Lymphoma;Hematology/Oncology Clinics of North America;2020-08
4. Engineering therapeutic bispecific antibodies using CrossMab technology;Methods;2019-02
5. Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia;Journal of Clinical Oncology;2018-09-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3